TrialNature communications2024

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.

Ming Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.